Catalent, novo nordisk and european commission

BRUSSELS/LONDON, Nov 22 (Reuters) - Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent (CTLT.N), opens new ...
Novo Holdings also invested a further €3.6 million into Danish company Minervax, a Lund University spin-out developing a prophylactic vaccine against Group B Streptococcus (GBS), responsible for ...
Catalent (CTLT) issued the following open letter to customers: “I want to correct a few key inaccuracies that have been reported in the press regarding Novo Holdings’ pending acquisition of ...
EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...
Life sciences tools company Esco Lifesciences Group has scored $200m in a series A and crossover round co-led by Novo Holdings and Vivo Capital. Funds will be used to expand the company's presence ...